Comparative Pharmacology
Head-to-head clinical analysis: ARAKODA versus HALFAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ARAKODA versus HALFAN.
ARAKODA vs HALFAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ARAKODA (tafenoquine) is an 8-aminoquinoline antimalarial agent that inhibits the conversion of Plasmodium protozoa from liver stage to blood stage, thereby preventing relapses. Its exact mechanism may involve interference with electron transport or generation of reactive oxygen species.
HALFAN (halofantrine) is an antimalarial agent that acts as a blood schizonticide. It is thought to inhibit the polymerization of heme into hemozoin, leading to toxic accumulation of free heme within the parasite's food vacuole. It may also interfere with nucleic acid synthesis.
400 mg orally once daily for 3 days, then 200 mg once daily for maintenance (up to 12 months).
Adults: 500 mg orally once daily.
None Documented
None Documented
Terminal elimination half-life: approximately 14-16 days (range 12-19 days) in healthy adults; this long half-life is due to extensive tissue distribution and slow release from tissues, providing prophylactic coverage for up to 4 weeks after a single dose.
Terminal elimination half-life is 10-18 hours (mean 14 hours) in healthy adults, allowing twice-daily dosing.
Biliary/fecal: ~90% unchanged; renal: <1% unchanged (dose-proportional urinary excretion of tafenoquine is minimal, with most eliminated via feces as unchanged drug and minor metabolites).
Primarily hepatic metabolism; renal excretion of metabolites accounts for <10% unchanged drug; biliary/fecal elimination of metabolites approximately 20-30%.
Category C
Category C
Antimalarial
Antimalarial